[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-371300-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-371300-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","extended-spectrum-of-cancers-in-ptenhamartoma-tumor-syndrome","Extended spectrum of cancers in PTENhamartoma tumor syndrome","","PTEN hamartoma tumor syndrome (PHTS) is associated with increased lifetime risks of several component cancers, but non-component cancers (NCC) have not been studied systematically. Among 701 research participants with PHTS, 340 (49%) developed cancer and 101 (30%) had at least one NCC; 70% of NCC cases also had another PHTS component malignancy. Pathogenic PTEN variants increased risks for prostate cancer and soft tissue sarcomas at younger ages. A literature review identified independent NCC cases with PTEN-related molecular changes, supporting second-hit somatic PTEN alterations in subsets.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/extended-spectrum-of-cancers-in-ptenhamartoma-tumor-syndrome/371300/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/extended-spectrum-of-cancers-in-ptenhamartoma-tumor-syndrome/371300.png","ImageObject",300,407,{"name":42,"@type":43},"Ezra","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-02","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"How common are non-component cancers in PTEN hamartoma tumor syndrome (PHTS)?","Question",{"text":63,"@type":64},"Among 701 participants with PHTS, 340 (49%) had cancer, and 101 (30%) had at least one non-component cancer (NCC).","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Do patients with NCC often also have other PHTS component malignancies?",{"text":68,"@type":64},"Yes. Of those with NCC, 70% had at least one other PHTS component malignancy.",{"name":70,"@type":61,"acceptedAnswer":71},"What additional cancer risks were observed for pathogenic PTEN variants?",{"text":72,"@type":64},"Pathogenic PTEN variants showed higher risks for prostate cancer and soft tissue sarcomas at younger ages than in the general population.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},371300,1790534416,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":112,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":117,"preview_page_count":33,"preview_urls":144},1099514068035,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","npj | precision oncology Article  \nPublished in partnership with The Hormel Institute, University of Minnesota  \n[https://doi.org/10.1038/s41698-025-00847-3](https://doi.org/10.1038/s41698-025-00847-3)  \nExtended spectrum of cancers in PTENhamartoma tumor syndrome  \n Check for updates  \n\n| Lamis Yehia1 , Gilman Plitt1,2,3, Ann M. Tushar1, Darren Liu1,3, Julia Joo1,3, Ying Ni4, Sujata Patil5 & Charis Eng1,3,6,7,8,9,10 |  |\n| --- | --- |\n| PTEN hamartoma tumor syndrome (PHTS) is associated with increased lifetime risks of breast, thyroid, kidney, endometrial, and colorectal cancers, as well as melanoma (collectively, component cancers) . We sought to characterize non-component cancers (NCC) in PHTS. Of 701 research participants with PHTS, 340 (49%) had cancer, with 101 (30%) having at least one NCC. Interestingly, 71 (70%) of those with NCC had at least one other PHTS component malignancy. Patients with pathogenic PTEN variants showed higher risks for prostate cancer and soft tissue sarcomas at younger ages than the general population. A literature survey showed independent cases of NCC in PHTS, with PTEN-related molecular changes including second-hit somatic PTEN alterations in a subset of various specimens. We recommend increased awareness regarding NCC in individuals with PHTS, particularly increased risks for prostate cancer and sarcoma. Further studies are needed to deﬁne age-related penetrance and accordingly, the appropriate strategies for cancer risk management. |  |\n| PTENhamartoma tumor syndrome (PHTS) is a term encompassing individuals with disease-causing germline PTEN variants regardless of clinical diagnosis1,2. PHTS includes Cowden syndrome (CS), Bannayan-RileyRuvalcaba syndrome (BRRS), PTEN-related Proteus syndrome (PS), and PTEN-related Proteus-like syndrome1. Even prior to the discovery of PTENas the ﬁrst susceptibility gene for CS, it was recognized that the syndrome was associated with elevated lifetime risks of breast and thyroid cancers3,4. Subsequent studies following the identiﬁcation of germline PTEN variants in individuals with CS led to the expansion of the spectrum of cancers associated with CS and the establishment of more accurate cancer risk assessment and surveillance strategies5–7.\u003Cbr>Studies in adult patients with PHTS indicate that germline PTEN variants are associated with increased lifetime risks of breast, thyroid, endometrial, kidney, and colon cancers, as well as melanoma (collectively referred toasPHTS component cancers)6,8–10. However, isolated reports and anecdotal evidence from our clinical practice (PTEN Multidisciplinary Clinic and Center of Excellence, Cleveland Clinic, Cleveland, Ohio, USA) show that | individuals with PHTS can also have other cancers beyond those known tobe associated with the syndrome (i.e., non-component cancers or NCC). Importantly, the spectrum of non-component cancers has not been systematically studied in PHTS. In addition, it is not known whether these cancers are incidental (i.e., sporadic) or whether they are bona ﬁde components of PHTS that were missed in earlier studies due to limited patient series. In this study, we report the spectrum ofnon-component cancers from a prospective international series of pediatric and adult patients with PHTS to inform prospective cancer risk assessment and surveillance recommendations.\u003Cbr>Results\u003Cbr>Patient characteristics and germline PTEN variant spectrum We prospectively accrued 701 research participants with germline PTEN variants from September 1, 2005, through January 6, 2022. Of the 701 research participants, 340 (49%) received cancer diagnoses (any cancer type), with 144 (42%) of those diagnosed with second primary malignant neoplasms(SMN). Ofthe340individuals with PHTSand cancer,101(30%) |\n\n1Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, 44195, USA. 2Department of General Surgery, Digestive Disease and Surgery Institute, Cleveland Clinic, Cleveland, OH, 44195, USA. 3Clev","cbCaia60gRyJE0Du","https://ap.wps.com/l/cbCaia60gRyJE0Du","pdf",428521,"English","# Results\n## Patient characteristics and germline PTEN variant spectrum\n## Table 1: Clinical characteristics of 340 patients with PHTS and cancer","[{\"question\":\"How common are non-component cancers in PTEN hamartoma tumor syndrome (PHTS)?\",\"answer\":\"Among 701 participants with PHTS, 340 (49%) had cancer, and 101 (30%) had at least one non-component cancer (NCC).\"},{\"question\":\"Do patients with NCC often also have other PHTS component malignancies?\",\"answer\":\"Yes. Of those with NCC, 70% had at least one other PHTS component malignancy.\"},{\"question\":\"What additional cancer risks were observed for pathogenic PTEN variants?\",\"answer\":\"Pathogenic PTEN variants showed higher risks for prostate cancer and soft tissue sarcomas at younger ages than in the general population.\"}]","Extended spectrum of cancers in PTENhamartoma tumor syndrome | PDF",1790191739,[145,149,153,157],{"page_no":22,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4e79c3691f4226b9f18c1a2c5150c8b7.webp",983,1305,{"page_no":26,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5a94a1396b269b9abb52834a6f88d2d2.webp",982,1304,{"page_no":30,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0c719f54e6e40e6042d680fdbb835ee8.webp",981,1303,{"page_no":33,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3faebe056e80a7961f80b0a0c0185ea2.webp",980,1301]